YOLFTbeta
Cellid Co. Ltd

Cellid Co. Ltd

299660 · KQ · Healthcare / Biotechnology

1,788.00KRW-17.00 (-0.94%)

Price History

Full chart

Market Stats

Previous Close1,805.00
Open1,834.00
Day Range1,736.00 – 1,834.00
52-Week Range973.00 – 4,760.00
Volume76.55K
Market Cap71.10B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta1.60
50-Day Avg2,103.26
200-Day Avg2,551.82

About

Cellid, Co., Ltd. develops immunotherapeutic vaccines for cancer and/or infectious diseases therapies. It is developing BVAC-C for cervical, head and neck, anal, and sex organ cancer with human papilloma virus infection; BVAC-B for stomach, breast, and ovarian cancer with HER-2/neu antigen; and BVAC-P for prostate cancer, renal cell cancer, and glioblastoma with prostate acid phosphatase (PAP) and prostate-specific membrane (PSMA) antigens. The company is also developing BVAC-M for cancers, such as melanoma with GP100/MAGE-A3 antigens; BVAC-Neo. Cellid, Co., Ltd. was founded in 2006 and is headquartered in Seoul, South Korea.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOYuil Kang Chang
  • Employees0
  • Headquarters142 dong Seoul National University, Seoul, South Korea, 08826, Korea
  • Websitehttps://www.cellid.co.kr

Leadership

  • Yuil Kang ChangCEO & Representative Director
  • SungHo LeeHead of Management Support Office & Executive Director

Financials

Income Statement

Currency: KRW2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue639.82M00000909.09M480.00M04.17B8.84B
Growth (%)--100.00%------47.20%-100.00%-+112.28%
Cost of Revenue-000000324.53M03.46B7.27B
Gross Profit639.82M00000909.09M155.47M0705.01M1.58B
Gross Margin100.00%-----100.00%32.39%-16.93%17.82%
Operating Expense1.26B1.06B1.52B2.37B3.53B5.29B13.92B15.07B11.90B12.49B12.92B
Operating Income-619.95M-1.06B-1.52B-2.37B-3.53B-5.29B-13.01B-14.91B-11.90B-11.79B-11.34B
Operating Margin-96.89%------1431.20%-3106.53%--283.00%-128.29%
EBITDA--------18.64B-7.68B-9.05B-9.41B
EBITDA Margin--------3882.54%--217.37%-106.45%
Net Income-1.13B-1.77B-5.41B-11.29B-2.49B-4.13B-13.07B-22.86B-11.61B-12.26B-12.07B
Net Income Margin-175.83%------1437.76%-4763.45%--294.33%-136.50%
R&D---1.76B2.06B3.17B7.43B7.89B5.04B3.49B3.95B
R&D as % of Total Revenue------816.91%1643.01%-83.71%44.70%
Interest Expense000010.73M12.55M536.29M1.63B1.26B471.96M142.49M
Interest Expense % of Total Revenue0.00%-----58.99%339.23%-11.33%1.61%

Balance Sheet

Currency: KRW2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets2.83B3.81B4.96B14.22B52.52B49.40B58.26B45.86B63.92B76.09B110.87B
Total Liabilities1.87B4.01B10.49B720.63M1.19B2.10B19.50B23.42B23.43B24.88B36.66B
Total Equity961.38M-205.83M-5.53B13.50B51.33B47.30B38.76B22.44B40.50B51.20B74.21B
Cash418.56M1.59B2.51B885.28M1.36B3.47B5.03B8.25B13.38B9.02B22.36B
Total Debt----50.54M54.43M-----
Net Debt------10.50B3.62B-4.05B5.26B

Cash Flow

Currency: KRW2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-1.50B-1.37B-1.99B-1.92B-3.76B-8.21B-12.22B-7.12B-10.32B-10.22B
Investing Cash Flow197.03M-305.30M-10.81B-37.10B5.17B-10.14B14.00B-751.88M-15.07B-
Financing Cash Flow2.48B2.60B11.18B39.82B386.95M20.09B1.26B12.99B21.03B-
Capital Expenditure125.97M19.60M5.82B4.28B11.72B3.11B1.20B11.28B18.42B25.39B
Free Cash Flow-----15.48B-11.32B-13.42B-18.40B-28.73B-35.61B
FCF to OCF----411.32%137.92%109.85%258.59%278.52%348.52%

Earnings

Report DateMar 31, 2019Jun 30, 2019Sep 30, 2019Dec 31, 2019Mar 31, 2020Jun 30, 2020Sep 30, 2020Dec 31, 2020Mar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate------------------------------
EPS Actual-40.53-69.40-55.81-71.75-129.113.43-113.23-151.29-271.98-228.05-272.36-453.70-451.73-390.67-368.50-930.33-331.92-337.93-313.05-101.87-241.94-192.08-157.38-169.91-127.06-115.92-80.46-152.65-50.27-644.81
Surprise------------------------------
Timing------------------------------

Key Statistics & Ratios

Market Cap71.10B
Enterprise Value94.14B
Trailing P/E0.00
Forward P/E0.00
Price / Sales7.43
Price / Book1.44
Revenue (TTM)4.17B
Gross Profit (TTM)697.69M
EBITDA-9.25B
Profit Margin0.00%
Operating Margin-768.16%
Return on Equity-26.74%
Return on Assets-10.70%
Shares Outstanding29.50M
Shares Float17.87M
Beta1.60
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Jul 18, 20231432:1305